Venbio Global Strategic Fund, L.p. - Net Worth and Insider Trading
Venbio Global Strategic Fund, L.p. Net Worth
The estimated net worth of Venbio Global Strategic Fund, L.p. is at least $149 Million dollars as of 2024-05-24. Venbio Global Strategic Fund, L.p. is the of ALX Oncology Holdings Inc and owns about 9,799,331 shares of ALX Oncology Holdings Inc (ALXO) stock worth over $147 Million. Venbio Global Strategic Fund, L.p. is the Director, 10% Owner of Precision BioSciences Inc and owns about 142,171 shares of Precision BioSciences Inc (DTIL) stock worth over $2 Million. Venbio Global Strategic Fund, L.p. is also the 10% Owner of Metacrine Inc and owns about 2,443,421 shares of Metacrine Inc (MTCR) stock worth over $3,421. Details can be seen in Venbio Global Strategic Fund, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Venbio Global Strategic Fund, L.p. has not made any transactions after 2021-10-25 and currently still holds the listed stock(s).
Transaction Summary of Venbio Global Strategic Fund, L.p.
Venbio Global Strategic Fund, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Venbio Global Strategic Fund, L.p. owns 3 companies in total, including Metacrine Inc (MTCR) , ALX Oncology Holdings Inc (ALXO) , and Precision BioSciences Inc (DTIL) .
Insider Ownership Summary of Venbio Global Strategic Fund, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| MTCR | Metacrine Inc | 2021-10-25 | 10 percent owner & other: See Remarks |
| ALXO | ALX Oncology Holdings Inc | 2020-07-21 | 10 percent owner & other: See Remarks |
| DTIL | Precision BioSciences Inc | 2019-04-01 | director & 10 percent owner |
Venbio Global Strategic Fund, L.p. Latest Holdings Summary
Venbio Global Strategic Fund, L.p. currently owns a total of 3 stocks. Among these stocks, Venbio Global Strategic Fund, L.p. owns 9,799,331 shares of ALX Oncology Holdings Inc (ALXO) as of July 21, 2020, with a value of $147 Million and a weighting of 98.77%. Venbio Global Strategic Fund, L.p. owns 142,171 shares of Precision BioSciences Inc (DTIL) as of April 1, 2019, with a value of $2 Million and a weighting of 1.23%. Venbio Global Strategic Fund, L.p. also owns 2,443,421 shares of Metacrine Inc (MTCR) as of October 25, 2021, with a value of $3,421 and a weighting of 0%.
Latest Holdings of Venbio Global Strategic Fund, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc | 2020-07-21 | 9,799,331 | 15.01 | 147,087,958 |
| DTIL | Precision BioSciences Inc | 2019-04-01 | 142,171 | 12.91 | 1,835,428 |
| MTCR | Metacrine Inc | 2021-10-25 | 2,443,421 | 0.00 | 3,421 |
Holding Weightings of Venbio Global Strategic Fund, L.p.
Venbio Global Strategic Fund, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 1 transactions in ALX Oncology Holdings Inc (ALXO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in ALX Oncology Holdings Inc is the acquisition of 853,000 shares on July 21, 2020, which cost Venbio Global Strategic Fund, L.p. around $16 Million.
According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 0 transactions in Precision BioSciences Inc (DTIL) over the past 5 years. The most-recent trade in Precision BioSciences Inc is the acquisition of 1,667 shares on April 1, 2019, which cost Venbio Global Strategic Fund, L.p. around $800,000.
According to the SEC Form 4 filings, Venbio Global Strategic Fund, L.p. has made a total of 2 transactions in Metacrine Inc (MTCR) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Metacrine Inc is the sale of 615,702 shares on October 25, 2021, which brought Venbio Global Strategic Fund, L.p. around $929,710.
Insider Trading History of Venbio Global Strategic Fund, L.p.
- 1
Venbio Global Strategic Fund, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Venbio Global Strategic Fund, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venbio Global Strategic Fund, L.p. is 0.83%. GuruFocus also compares Venbio Global Strategic Fund, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venbio Global Strategic Fund, L.p. within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Venbio Global Strategic Fund, L.p.'s insider trading performs compared to the benchmark.
Performance of Venbio Global Strategic Fund, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 9.9 | | | | | |
| Relative Return to S&P 500(%) | 6.16 | | | | | |
Venbio Global Strategic Fund, L.p. Ownership Network
Venbio Global Strategic Fund, L.p. Owned Company Details
What does Metacrine Inc do?
Who are the key executives at Metacrine Inc?
Venbio Global Strategic Fund, L.p. is the 10 percent owner & other: See Remarks of Metacrine Inc. Other key executives at Metacrine Inc include Chief Business Officer Michael York , director & President & CEO Preston Klassen , and 10 percent owner Braden Michael Leonard .
Metacrine Inc (MTCR) Insider Trades Summary
Over the past 18 months, Venbio Global Strategic Fund, L.p. made no insider transaction in Metacrine Inc (MTCR). Other recent insider transactions involving Metacrine Inc (MTCR) include a net sale of 380,605 shares made by Preston Klassen , a net purchase of 271,605 shares made by Braden Michael Leonard , and a net sale of 107,054 shares made by Michael York .
In summary, during the past 3 months, insiders sold 0 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 487,659 shares of Metacrine Inc (MTCR) were sold and 271,605 shares were bought by its insiders, resulting in a net sale of 216,054 shares.
Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Metacrine Inc Insider Transactions
Venbio Global Strategic Fund, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Venbio Global Strategic Fund, L.p.. You might contact Venbio Global Strategic Fund, L.p. via mailing address: 1700 Owens Street, Suite 595, San Francisco Ca 94158.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
